Spinal Cord Series and Cases, 2016 · DOI: 10.1038/scsandc.2015.37 · Published: April 7, 2016
This case report describes a man with tetraplegia who developed ocular myasthenia gravis (OMG). The OMG diagnosis was complicated by his existing conditions and medications. Managing his OMG symptoms created new problems with bladder control and blood pressure. The patient's OMG was treated with pyridostigmine, which helped his eye symptoms but worsened his abdominal spasms and autonomic dysreflexia. Doctors had to stop the pyridostigmine and find another way to manage his double vision. Ultimately, the patient's OMG was managed with an eye patch to alleviate double vision. He continued to have health problems and died five months later from a heart attack.
Clinicians should consider OMG in patients with tetraplegia presenting with new ocular symptoms, even if typical patterns are masked.
Careful consideration of drug interactions and side effects is crucial when treating OMG in patients with SCI due to potential conflicts with existing medications.
Managing OMG in tetraplegic patients requires a collaborative approach involving neurologists, spinal cord injury specialists, and other healthcare professionals.